home Archives - Break Through Cancer

February 24, 2026February 26, 2026

2025 Year in Review: Our Scientific Progress and Clinical Impact

Accelerating Discovery: Break Through Cancer’s 2nd Annual Hackathon Break Through Cancer’s 2025 Year in Review captures a year of measurable scientific progress across our TeamLabs, from advancing multi-site clinical trials to scaling data infrastructure and publishing high-impact research. Together, these efforts reflect the power of radical collaboration™ to drive progress against the deadliest cancers. 📖 Explore the 2025 Year in ReviewJTNDaWZyYW1lJTIwYWxsb3dmdWxsc2NyZWVuJTNEJTIyYWxsb3dmdWxsc2NyZWVuJTIyJTIwYWxsb3clM0QlMjJjbGlwYm9hcmQtd3JpdGUlMjIlMjBzY3JvbGxpbmclM0QlMjJubyUyMiUyMGNsYXNzJTNEJTIyZnAtaWZyYW1lJTIyJTIwc3JjJTNEJTIyaHR0cHMlM0ElMkYlMkZoZXl6aW5lLmNvbSUyRmZsaXAtYm9vayUyRmY4YWIyYzllYzkuaHRtbCUyMiUyMHN0eWxlJTNEJTIyYm9yZGVyJTNBJTIwMXB4JTIwc29saWQlMjBsaWdodGdyYXklM0IlMjB3aWR0aCUzQSUyMDEwMCUyNSUzQiUyMGhlaWdodCUzQSUyMDQwMHB4JTNCJTIyJTNFJTNDJTJGaWZyYW1lJTNF 📖 Watch the 2025 Highlight Video...

February 3, 2026February 4, 2026

New Coalition of Leading Cancer Research Organizations Launched to Accelerate Early Detection of Deadly Cancers

New Coalition of Leading Cancer Research Organizations Launched to Accelerate Early Detection of Deadly Cancers $12 million awarded to six collaborative teams developing new approaches to the earlier detection and diagnosis of pancreatic, ovarian, and esophageal cancers News Release For Immediate Release Media Contact: Soracha Ward soracha.ward@breakthroughcancer.org New York, NY, February 3, 2026 — The Mark Foundation for Cancer Research today announced the launch of a coalition of leading nonprofit organizations dedicated to solving the critical problem of early detection and diagnosis for some of the world’s deadliest cancers. In partnership with the American Association for Cancer Research (AACR), Lustgarten Foundation,......

December 11, 2025February 10, 2026

Five Leading Cancer Centers Unite to Target CD123 and Eradicate Hidden Leukemia Cells

Five Leading Cancer Centers Unite to Target CD123 and Eradicate Hidden Leukemia Cells A multi-site trial pairs targeted therapy with next-generation MRD testing to track residual disease and uncover vulnerabilities in leukemia cells News Release For Immediate Release Media Contact: Soracha Ward soracha.ward@breakthroughcancer.org (CAMBRIDGE, MASS.) December 11, 2025 – Acute myeloid leukemia (AML) is an aggressive blood cancer, with overall survival remaining approximately 30% at five years despite advances in therapy. Even when patients achieve remission, the disease often returns, fueled by a small number of leukemia cells that survive initial treatment, known as measurable residual disease (MRD). These remaining......

November 26, 2025February 10, 2026

More Than a Patient: How Holly Folgia Turned Her Cancer Journey Into Impact

More Than a Patient: How Holly Folgia Turned Her Cancer Journey Into Impact Holly's journey with stage IV ovarian cancer is one of resilience, creativity, and generosity. As a participant in a Break Through Cancer-funded clinical trial at Memorial Sloan Cancer Center, she is a part of the Targeting Minimal Residual Disease in Ovarian Cancer TeamLab's work to bring new treatment options to patients facing one of the deadliest cancers for women. While undergoing treatment, Holly published a children's book, I Hope You Know, a heartfelt story about the bond between mother and child. She is donating half of the proceeds to ovarian and......

November 21, 2025

One Surgery Could Prevent Most Ovarian Cancers, Surgeons Say | The ASCO Post

One Surgery Could Prevent Most Ovarian Cancers, Surgeons Say November 20, 2025 Known as “the silent killer” due to its lack of symptoms and reliable screening tests, ovarian cancer remains one of the deadliest gynecologic cancers, claiming more than 12,000 lives annually. At a recent meeting, experts said that performing a single preventive procedure within general surgery could stop many ovarian cancers from ever developing. Read More at The ASCO Post....

November 20, 2025November 20, 2025

Conquering Cancer: Innovations Closing Gaps and Improving Outcomes | Milken Institute

Jesse Boehm at the Future of Health Summit 2025: Conquering Cancer Panel We are pleased to share that our Chief Scientific Officer, Jesse Boehm, participated as a speaker at the 2025 Future of Health Summit, hosted by the Milken Institute in Washington, DC. The Summit brought together more than 200 experts and 1,400 participants to discuss biomedical innovation, equitable access, chronic disease prevention, and the future of global health. As part of the program, Jesse joined the panel “Conquering Cancer: Innovations, Closing Gaps and Improving Outcomes,” contributing perspectives on the power of radical collaboration and team-science models to accelerate progress......

November 19, 2025November 21, 2025

Canadian scientists join international osteosarcoma team to solve aggressive cancer that targets children and young adults | Globe and Mail

Canadian scientists join international osteosarcoma team to solve aggressive cancer that targets children and young adults November 14, 2025 More than 45 years after Terry Fox ran his Marathon of Hope, a new generation of scientists—backed by a coalition of donors and home-grown Canadian ingenuity—unites to defeat osteosarcoma, the cancer that took Terry's life. Read More at Globe and Mail....

November 18, 2025November 21, 2025

One Surgery Could Prevent Most Ovarian Cancers, Surgeons Say | American College of Surgeons

One Surgery Could Prevent Most Ovarian Cancers, Surgeons Say November 17, 2025 Expanding access to fallopian tube removal during planned abdominal surgeries in post-reproductive women could save thousands of lives every year. Read More at American College of Surgeons...

October 10, 2025October 14, 2025

Real-Time Biopsies Reveal Hidden Insights into Glioblastoma Therapy Response | Bioengineer.org

Real-Time Biopsies Reveal Hidden Insights into Glioblastoma Therapy Response October 08, 2025 In a groundbreaking advancement for glioblastoma research, scientists from Break Through Cancer’s Accelerating Glioblastoma Therapies Through Serial Biopsies TeamLab have demonstrated that the oncolytic virus therapy, CAN-3110, sparks a profound and previously undetectable immune response deep within recurrent glioblastoma tumors. Read More at Bioengineer.org...

October 10, 2025

Experimental Glioblastoma Trial Findings Could Lead to Change in Patient Monitoring and Therapy | GEN

Experimental Glioblastoma Trial Findings Could Lead to Change in Patient Monitoring and Therapy October 08, 2025 Researchers headed by teams at Mass General Brigham Cancer Institute and Harvard Medical School have acquired serial biopsies from two recurrent glioblastoma (rGBM) patients who were involved in an immunotherapy clinical trial, allowing the scientists to safely monitor brain tumor progression and the patients’ responses to treatment. The researchers say their approach captured details that are indiscernible by even the most advanced of imaging methods. Read More at Genetic Engineering and Biotechnology News...